171 related articles for article (PubMed ID: 37805657)
21. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
[TBL] [Abstract][Full Text] [Related]
22. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
23. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
24. The homeobox transcription factor Prox1 inhibits proliferation of hepatocellular carcinoma cells by inducing p53-dependent senescence-like phenotype.
Chang TM; Hung WC
Cancer Biol Ther; 2013 Mar; 14(3):222-9. PubMed ID: 23291986
[TBL] [Abstract][Full Text] [Related]
25. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
[TBL] [Abstract][Full Text] [Related]
26. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
28. Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence.
Luis G; Godfroid A; Nishiumi S; Cimino J; Blacher S; Maquoi E; Wery C; Collignon A; Longuespée R; Montero-Ruiz L; Dassoul I; Maloujahmoum N; Pottier C; Mazzucchelli G; Depauw E; Bellahcène A; Yoshida M; Noel A; Sounni NE
Redox Biol; 2021 Jul; 43():102006. PubMed ID: 34030117
[TBL] [Abstract][Full Text] [Related]
29. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
[TBL] [Abstract][Full Text] [Related]
30. SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.
Li Z; Liao X; Hu Y; Li M; Tang M; Zhang S; Mo S; Li X; Chen S; Qian W; Feng R; Yu R; Xu Y; Yuan S; Xie C; Li J
Free Radic Biol Med; 2023 May; 201():41-54. PubMed ID: 36924851
[TBL] [Abstract][Full Text] [Related]
31. p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma.
Zhang B; Wang X; Deng J; Zheng H; Liu W; Chen S; Tian J; Wang F
Cancer Lett; 2019 Sep; 459():50-58. PubMed ID: 31163195
[TBL] [Abstract][Full Text] [Related]
32. SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway.
Huang GM; Jiang QH; Cai C; Qu M; Shen W
Cancer Lett; 2015 Mar; 358(2):180-190. PubMed ID: 25528629
[TBL] [Abstract][Full Text] [Related]
33. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
[TBL] [Abstract][Full Text] [Related]
34. Role of ferroptosis in hepatocellular carcinoma.
Nie J; Lin B; Zhou M; Wu L; Zheng T
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2329-2337. PubMed ID: 30167889
[TBL] [Abstract][Full Text] [Related]
35. CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.
He XX; Zhang YN; Yan JW; Yan JJ; Wu Q; Song YH
Tumour Biol; 2016 Jan; 37(1):807-15. PubMed ID: 26250460
[TBL] [Abstract][Full Text] [Related]
36. Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.
Yao JY; Xu S; Sun YN; Xu Y; Guo QL; Wei LB
Acta Pharmacol Sin; 2022 Apr; 43(4):1033-1045. PubMed ID: 34188177
[TBL] [Abstract][Full Text] [Related]
37. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma.
Li H; Liu Y; Jiang W; Xue J; Cheng Y; Wang J; Yang R; Zhang X
BMC Cancer; 2021 Mar; 21(1):318. PubMed ID: 33765973
[TBL] [Abstract][Full Text] [Related]
38. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.
Sun X; Niu X; Chen R; He W; Chen D; Kang R; Tang D
Hepatology; 2016 Aug; 64(2):488-500. PubMed ID: 27015352
[TBL] [Abstract][Full Text] [Related]
39. PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma.
Liu Y; Ouyang L; Mao C; Chen Y; Li T; Liu N; Wang Z; Lai W; Zhou Y; Cao Y; Liu S; Liang Y; Wang M; Liu S; Chen L; Shi Y; Xiao D; Tao Y
Oncogene; 2022 Jul; 41(27):3570-3583. PubMed ID: 35688944
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
